Nippon Soda Co., Ltd.
Special low viscosity, super fine powder grade Nisso HPC-SSL-SFP is introduced as a new high performance dry binder for direct compression, ODT and extra-granule addition applications.
Special low viscosity, super fine powder grade Nisso HPC-SSL-SFP is introduced as a new high performance dry binder for direct compression, ODT and extra-granule addition applications. The excellent tablet properties that HPC is well known for as a wet binder can now be achieved in dry binding applications using very low levels of binder and with minimal-to-no impact on disintegration times and dissolution profiles.
When HPC-SSL-SFP is added to an Acetaminophen DC tablet (Acetaminophen 60%, Lactose/Corn Starch 24.5-36.5%, Binder 3-15%, Silica 0.5%) as a dry binder at 3% vs 15% for other typical dry binders, tablet hardness and friability are superior while disintegration time is fastest and dissolution time is not adversely impacted.
The highly compressible HPC-SSL-SFP is also effective in ODT formulations and in extra-granule dry binder addition applications.
Click here to download a white paper with complete data.
Contact info:
Catherine Cote
c.cote@nissoamerica.com
Nisso America Inc.
88 Pine Street, 14th Fl
New York, NY 10005
+1-212-490-0350
www.nissoexcipients.com
Nisso Chemical Europe GmbH
Naoki Kuwada
kuwada@nisso-chem.de
+49-(0)-211-1306686-0
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
